<DOC>
	<DOCNO>NCT01668134</DOCNO>
	<brief_summary>This study do determine target radiation therapy ( stereotactic ) give treat liver cancer , patient unable undergo surgery , short period time small amount side effect .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy Hepatocellular Carcinoma , Intrahepatic Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Age ≥ 18 Karnofsky Performance Status ≥ 60 Pathologically confirm IHC HCC . ( Pathology require HCC lesion enhances typically MRI patient evaluate liver transplant surgery team think HCC . ) 4 less separate intrahepatic lesion , least one lesion able follow EASL Criteria . Local surgical resection possible due tumor patient factor Limited metastatic disease allow volume metastatic disease exceed volume primary disease . Prior TACE allow stopped/completed least 2 week prior enrollment Prior chemotherapy except Sorafenib allow stopped/completed least 2 week prior enrollment Prior Sorafenib allow stopped/completed least seven day prior enrollment . Able provide sign informed consent ChildsPugh score 9 ALT AST ≥ 6 x upper limit normal Prior history abdominal irradiation Women pregnant nursing Scheduled undergo chemotherapy except Sorafenib time radiation therapy give , 4 week completion radiation therapy . Scheduled undergo Sorafenib within seven day radiation therapy deliver , 2 week completion radiation therapy . Undergone prior radiation therapy abdomen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>